


Brexit and health: What's at risk in the event of a no-deal?



Supporting healthcare as the UK leaves the EU

Research and innovation

The prospect of a no-deal is already having an impact on pharmaceutical research. Medical research firm Recardio has suspended all UK activities due to uncertainty about how new medicines will be approved after Brexit. The 114 NHS trusts currently involved in European Reference Networks, will be excluded.




Regulation

Patients in the UK could face additional delays in accessing new medicines, as the Swiss model has shown. It is estimated that as a smaller market, Switzerland gains access to new medicines 157 days later on average than the EU.



Medical supply chains

Trade between the UK and the EU is substantial, delivering medicines and medical devices to patients across Europe. For medicines, 45 million patient packs go to the EU from the UK every month, and 37 million patient packs go from the EU to the UK. Medical supply chains could be affected in the instance of a no-deal.



Reciprocal healthcare

Reciprocal healthcare agreements will end. 190,000 UK pensioners living in the EU currently have the right to receive healthcare in the member state in which they reside. In the event of a no-deal, there could be an impact on NHS services if some people decided to return to the UK for treatment.



Public health and disease prevention

If the UK no longer had a relationship with the European Centre for Disease Prevention and Control, both UK and European health protection will be weakened due to a reduction in information exchange.



For further information about the work of the Brexit Health Alliance, please visit www.nhsconfed.org/brexithealthalliance